Investor profile
Saturn Partners
Micro-fund
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Since 1994, Saturn Partners has taken an active role in the formation and management of seed and early-stage companies, believing these investments offer the best opportunity to influence a company's success and produce top-decile returns. The firm seeks innovative solutions at the leading edge of industry trends — particularly in information and financial technology, advanced materials, and healthcare technology — targeting companies with disruptive, hard-to-replicate technology that addresses a critical market need. Saturn specializes in identifying promising companies in locations underserved by other VC firms, with a particular presence in Boston, Pittsburgh, Los Angeles, and New York, on the thesis that great ideas and strong talent are not confined to traditional VC hubs and that deals in these regions are priced more reasonably and companies are more receptive to outside guidance.
Notable quotes
“Panopto would not be where it is today without Bill Guttman's guidance and Saturn's support. Bill is a rare asset for a young technology company, with a strong grasp of business, a keen sense for winning technology, and a nuanced and thoughtful leadership style.”
“Saturn Partners are entrepreneur's friend. I had the pleasure to work with Bill Guttman closely and he has been a valuable board member. I have found him to be extremely useful in many situations related to financing needs or discussing a product or go to market strategies. His years of fin-tech experience shows in the way he supports our team.”
“As a company whose core technology is catalysts, we know a good catalyst when we meet one and Jeff McCormick and the team at Saturn Partners have proven to be just that for our business. Saturn has provided the value beyond capital alone that early stage companies greatly benefit from.”
Team
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Areteia Therapeutics | Series A | $75m | 2024-02-13 |
| Plai Labs | Seed | $32m | 2023-01-19 |
| Omaze | Series C | $85m | — |
| YieldStreet | Seed | $3m | 2016-05-04 |
| Panopto | Series Unknown | $4m | 2011-01-01 |
| Knopp Biosciences | Series Unknown | — | — |
| Constant Contact | Series Unknown | — | — |
| Alignable | Series Unknown | — | — |
| Trunomi | Seed | $3m | — |
| Third Pole Therapeutics | Series Unknown | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Biogen Idec | 2 |
| Bain Capital Life Sciences | 2 |
| ARCH Venture Partners | 2 |
| ff Venture Capital | 2 |
| Greylock Partners | 1 |
| Kleiner Perkins | 1 |
Fit check
Is Saturn Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit